| Literature DB >> 33164754 |
Kellie Wang1, Haden Geiger2, Andre McMahon3.
Abstract
Tranexamic acid (TXA) is an antifibrinolytic agent which inhibits conversion of plasminogen to plasmin, a key step in kallikrein activation and bradykinin formation. Tranexamic acid is used in prophylactic management of hereditary angioedema; however, evidence for TXA in angiotensin converting enzyme (ACE) inhibitor-induced angioedema (ACEI-AE) is limited. We describe a patient who presented to the emergency department with ACEI-AE who was successfully treated with TXA. This case suggests that TXA may be a beneficial treatment modality in the management of ACEI-AE and warrants further investigation.Entities:
Keywords: ACE inhibitor; Angioedema; Bradykinin; Tranexamic acid
Mesh:
Substances:
Year: 2020 PMID: 33164754 DOI: 10.1016/j.ajem.2020.10.029
Source DB: PubMed Journal: Am J Emerg Med ISSN: 0735-6757 Impact factor: 2.469